Single Source Procurement: Opioid Overdose Prevention Program

Pursuant to New York State Finance Law § 163.10(b), The New York State Department of Health is presenting the following summary of relevant circumstances, and material and substantial reasons why a competitive procurement was not feasible. Adapt Pharma is the sole manufacturer of Narcan®. This product was approved by the Food Drug Administration (FDA) on November 15, 2015 and has a patent (patent 9480644) until March 16, 2035. The Narcan® will be provided to opioid overdose prevention programs registered with the NYS DOH AIDS Institute. Adapt Pharma will fill orders approved by the AIDS Institute and ship the naloxone to the registered opioid overdose prevention programs.

Procurement / Program Name	Opioid Overdose Prevention Program
Contractor Name(s)	Adapt Pharma, Inc.
Contract Period	8/1/2017 to 7/31/2020
Contract Number	C033007